Farnum Rhonda 4

What Happened

• Rhonda Farnum, SVP, Commercial & Medical Affairs at Theravance Biopharma (TBPH), sold a total of 31,067 shares on 2026-03-16 in three open-market transactions. The reported sale amounts were 7,767 shares @ $13.92 ($108,088), 15,534 shares @ $14.00 ($217,476), and 7,766 shares @ $13.92 ($108,073), for aggregate proceeds of approximately $433,637. These are disposals (sales), which are typically routine liquidity events rather than affirmative bullish purchases.

Key Details

• Transaction date: 2026-03-16; Form filed: 2026-03-18 (timely within the 2-business-day Form 4 window).
• Reported per-trade figures: 7,767 @ $13.92 ($108,088); 15,534 @ $14.00 ($217,476); 7,766 @ $13.92 ($108,073).
• Footnote: Trades were executed in multiple fills at prices from $13.755 to $14.01; prices above reflect the weighted average. The filer will provide detailed fill-level info on request (Footnote F1).
• Plan: Transactions were executed under the reporting person’s 10b5-1 trading plan dated 09/03/2025 (prearranged plan).
• Shares owned after transaction: not specified in the excerpt of the filing provided.

Context

• This was an open-market sale under a pre-established 10b5-1 plan, which is commonly used by insiders to sell shares on a set schedule and is generally considered a routine liquidity mechanism rather than an ad-hoc signal about company prospects.
• Filing was timely (filed two days after the transactions), so there is no late-filing concern noted in the provided information.